Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of COVID-19 on Psoriasis Practice

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04581044
Recruitment Status : Completed
First Posted : October 9, 2020
Last Update Posted : November 13, 2020
Sponsor:
Information provided by (Responsible Party):
Mona El-Kalioby, Cairo University

Brief Summary:

COVID-19 had a major impact on dermatology practice globally with special emphasis on chronic diseases e.g. psoriasis. The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis management.

This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian dermatologists.


Condition or disease
Psoriasis Covid19

Layout table for study information
Study Type : Observational
Actual Enrollment : 197 participants
Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: Impact of COVID-19 on Psoriasis Practice: A Cross Sectional Study
Actual Study Start Date : September 17, 2020
Actual Primary Completion Date : October 23, 2020
Actual Study Completion Date : October 23, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis




Primary Outcome Measures :
  1. Questionnaire to assess 1) Prescription pattern for Psoriasis patients during COVID-19 2) Management pattern for Psoriasis patients during COVID-19 [ Time Frame: 2-4 weeks ]
  2. Questionnaire to assess 1) Impact of COVID-19 on the course of psoriasis in patients 2) Impact of COVID-19 on the psoriasis patients behaviour [ Time Frame: 2-4 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Egyptian Dermatologists
Criteria

Inclusion Criteria:

  • Egyptian Dermatologists

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04581044


Locations
Layout table for location information
Egypt
Department of Dermatology, Cairo University
Cairo, Egypt
Sponsors and Collaborators
Cairo University
Layout table for additonal information
Responsible Party: Mona El-Kalioby, Dr., Cairo University
ClinicalTrials.gov Identifier: NCT04581044    
Other Study ID Numbers: KAPU2020 10
First Posted: October 9, 2020    Key Record Dates
Last Update Posted: November 13, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mona El-Kalioby, Cairo University:
Psoriasis
coronavirus
Sars-Cov-2
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases